AI
| Followers | 1733 |
| Posts | 210189 |
| Boards Moderated | 11 |
| Alias Born | 01/02/2008 |
Wednesday, June 01, 2011 7:48:37 PM
SNSS charts- could run until Monday
Sunesis Pharmaceuticals Corporate Update Call
Scheduled to start Mon, Jun 6, 2011, 9:00 am Eastern
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead product candidate is Voreloxin, an anticancer quinolone derivative (AQD) for the treatment of cancer. The company is conducting various clinical trials of Voreloxin, including a Phase 2 clinical trial, known as the REVEAL-1 trial, in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in platinum-resistant ovarian cancer patients. It has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and marketing of Voreloxin; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of Raf kinase and up to five additional targets that play a role in oncology and immunology indications. The company, formerly known as Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California
Sunesis Pharmaceuticals Corporate Update Call
Scheduled to start Mon, Jun 6, 2011, 9:00 am Eastern
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead product candidate is Voreloxin, an anticancer quinolone derivative (AQD) for the treatment of cancer. The company is conducting various clinical trials of Voreloxin, including a Phase 2 clinical trial, known as the REVEAL-1 trial, in previously untreated elderly patients with acute myeloid leukemia (AML); a Phase 1b/2 clinical trial combining Voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML; and a Phase 2 single agent clinical trial in platinum-resistant ovarian cancer patients. It has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and marketing of Voreloxin; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of Raf kinase and up to five additional targets that play a role in oncology and immunology indications. The company, formerly known as Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
